Case study demonstrates the exciting potential of Avacta's    PD-L1 Affimer biotherapeutics


Targeting the body's own immune responses against cancer is the most promising advance in the treatment of tumours in recent years. Our case study highlights the use of Affimer technology for the rapid generation of candidate biotherapeutics to inhibit a cancer immune checkpoint.

For a greater insight into Affimer technology and how it is being used to rapidly generate highly specific Affimer biotherapeutics, download our case study - ‘Identification of specific PD-L1 Affimer inhibitors with therapeutic potential’.

Complete the form to download the case study.

By registering your email you agree to receive further updates from Avacta Life Sciences about our products and services which are specific to your areas of interest.